Skip to content
10-Q

Quarterly Report

Cue Biopharma, Inc. CUE

0001193125-26-224091

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 4.05M sh
Shares Diluted Q1 2026 · Mar 31, 2026 4.81M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 2.48M sh
Capex Q1 2026 · Mar 31, 2026 $121K
Capex Q1 2026 · Mar 31, 2025 $150K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$10.94M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.17M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $16.38M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $27.14M
Stockholders Equity Q1 2026 · Mar 31, 2026 $21.61M
Stockholders Equity Q1 2026 · Dec 31, 2025 $26.43M
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.58M
Stockholders Equity Q1 2026 · Dec 31, 2024 $17.5M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.49M
Total Liabilities Q1 2026 · Mar 31, 2026 $9.27M
Total Liabilities Q1 2026 · Dec 31, 2025 $15.78M
Current Assets Q1 2026 · Mar 31, 2026 $26.39M
Current Assets Q1 2026 · Dec 31, 2025 $36.98M
Total Assets Q1 2026 · Mar 31, 2026 $30.88M
Total Assets Q1 2026 · Dec 31, 2025 $42.21M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.08
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$4.95
Eps Basic Q1 2026 · Mar 31, 2026 −$1.08
Eps Basic restated Q1 2026 · Mar 31, 2025 −$4.95
Sga Expense Q1 2026 · Mar 31, 2026 $4.15M
Sga Expense Q1 2026 · Mar 31, 2025 $4.17M
Rd Expense Q1 2026 · Mar 31, 2026 $6.9M
Rd Expense Q1 2026 · Mar 31, 2025 $8.55M
Net Income Q1 2026 · Mar 31, 2026 −$5.18M
Net Income Q1 2026 · Mar 31, 2025 −$12.26M
Operating Income Q1 2026 · Mar 31, 2026 −$5.35M
Operating Income Q1 2026 · Mar 31, 2025 −$12.3M
Revenue Q1 2026 · Mar 31, 2026 $5.69M
Revenue Q1 2026 · Mar 31, 2025 $421K